Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- URI -4.4% (in sympathy with lower FY23 revenue guidance from ASHTF)
Other news:
- BMY -4.1% (BMY and 2seventy bio (TSVT) announce the U.S. FDA's Oncologic Drugs Advisory Committee will meet to review data supporting the supplemental Biologics License Application for Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study)
- PRDO -3.4% (appoints Todd Nelson as President and CEO; Andrew Hurst resigned on Nov 15)
- NKLA -1.0% (CFO Anastasiya Pasterick to resign)
Analyst comments:
- CHGG -4.6% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- DNUT -1.8% (downgraded to Neutral from Overweight at JPMorgan)
- GGB -1.7% (downgraded to Neutral from Buy at BofA Securities)
- ENR -1.3% (downgraded to Neutral from Buy at UBS)